Clinical trials: Poorly Differentiated Thyroid Carcinoma
Anaplastic Thyroid Cancer, Insular Thyroid Cancer
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
Phase II trial to study the effectiveness of sorafenib tosylate in treating patients who have locally advanced, metastatic, or locally recurrent thyroid cancer.
- Conditions
- Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage III Follicular Thyroid Cancer
- Trial name
- NCT00095693
- Testing
- sorafenib tosylate, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Differentiated Thyroid Cancer, Metastatic Poorly Differentiated Thyroid Cancer
Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
The goal of this study is to determine the activity of sorafenib in patients with advanced (metastatic or recurrent) thyroid cancer.
- Conditions
- Metastatic Differentiated Thyroid Cancer, Metastatic Poorly Differentiated Thyroid Cancer, Metastatic Anaplastic Thyroid Cancer, Metastatic Medullary Thyroid Cancer
- Trial name
- NCT00654238
- Testing
- sorafenib
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- University of Pennsylvania
Breast Cancer, Head and Neck Cancer
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00937417
- Testing
- docetaxel, vandetanib, proteomic profiling
- Sponsor
- SWOG Cancer Research Network
Thyroid Cancer, Thyroid Cancer, Follicular
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
The purpose of this study is to find out whether a drug called PDR001, combined with either trametinib or dabrafenib, is a safe and effective treatment for thyroid cancer.
- Conditions
- Thyroid Cancer, Thyroid Cancer, Follicular, Papillary Thyroid Cancer, Follicular Thyroid Cancer
- Trial name
- NCT04544111
- Testing
- Trametinib, Dabrafenib, PDR001
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
Background: The thyroid is a gland at the base of the throat. Thyroid cancer is a disease that people get when abnormal cells begin to grow in this gland.
- Conditions
- Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT03002623
- Testing
- CUDC-907
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Neoplasms
Study of Clinical Outcomes of Thyroid Cancer
The Italian Thyroid Cancer Observatory (ITCO) repository was established to collect data on thyroid cancer management in a prospective and consecutive series of newly-diagnosed patients, enrolled in centers uniformly distributed…
- Trial name
- ITCO (NCT04031339)
- Testing
- Standard treatment
- Where
- 35 sites in Italy
- Volunteers
- 15,000 people
- Sponsor
- University of Roma La Sapienza
Advanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
This is a multicenter, open-label, multi-cohort Phase II exploratory study designed to evaluate the efficacy and safety of sacituzumab tirumotecan with or without tislelizumab in patients with unresectable, locally advanced, or…
- Conditions
- Advanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Carcinoma
- Trial name
- NCT07068542
- Testing
- Sacituzumab Tirumotecan (SKB264) plus Tislelizumab, Sacituzumab Tirumotecan (SKB264)
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Zhejiang Provincial People's Hospital
Thyroid Carcinoma, Thyroid Cancer
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
The purpose of this study is to develop a new drug treatment to reverse tumor resistance to radioiodine in BRAF mutant tumors so that radioiodine can be given to shrink tumors.
- Conditions
- Thyroid Carcinoma, Thyroid Cancer, Thyroid Cancer, Follicular, Thyroid Cancer (Follicular Cell)
- Trial name
- NCT04462471
- Testing
- I-124 PET/CT lesion dosimetry, Vemurafenib, Copanlisib
- Where
- 7 sites in United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Thyroid Cancer
Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer
To explore the efficacy and safety of selective coverage radiotherapy in poorly differentiated and anaplastic thyroid cancer
- Trial name
- NCT07777536
- Testing
- Selective coverage radiotherapy, comprehensive coverage radiotherapy
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Fudan University
Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer
Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer
The current study aims to explore the potential advantages of chemotherapy that is implemented based on drug sensitivity testing.
- Trial name
- NCT06713057
- Testing
- Cyclophosphamide+Pemetrexed+5-Fluorouracil, Cyclophosphamide+Doxorubicin+5-Fluorouracil, Vindesine + Cisplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Colorectal Cancer, Endometrial Cancer
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 and/or sargramostim may be a more effective treatment for solid tumors.
- Conditions
- Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00019331
- Testing
- aldesleukin, ras peptide cancer vaccine, sargramostim
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Follicular Thyroid Cancer, Insular Thyroid Cancer
Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
This randomized phase II trial studies how well dabrafenib works with or without trametinib in treating patients with recurrent thyroid cancer.
- Conditions
- Follicular Thyroid Cancer, Insular Thyroid Cancer, Papillary Thyroid Cancer, Recurrent Thyroid Cancer
- Trial name
- NCT01723202
- Testing
- dabrafenib, trametinib
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- Bhavana Konda
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma
Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer
The aim of the study is to evaluate the efficacy of the combination of lenvatinib with pembrolizumab, and to establish a safe and effective systemic treatment regimen for patients with metastatic anaplastic thyroid cancer (ATC) /…
- Conditions
- Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Thyroid Gland Anaplastic Carcinoma by AJCC V8 Stage
- Trial name
- NCT04731740
- Testing
- Lenvatinib, Pembrolizumab, Chemotherapy
- Where
- Russia
- Sponsor
- Saint Petersburg State University, Russia
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
This phase II trial tests how well XL092 works for the treatment of patients with differentiated thyroid cancer that has not responded to previous treatment with radioiodine (radioiodine refractory) and that has spread to nearby…
- Conditions
- Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma, Locally Advanced Thyroid Gland Follicular Carcinoma, Locally Advanced Thyroid Gland Oncocytic Carcinoma
- Trial name
- NCT06959641
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Jochen Lorch
Head and Neck Cancer
Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer
RATIONALE: Celecoxib may stop the growth of thyroid cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth.
- Trial name
- NCT00061906
- Testing
- celecoxib
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Insular Thyroid Cancer, Recurrent Thyroid Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with metastatic and/or locally advanced or locally recurrent thyroid cancer.
- Conditions
- Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer, Stage II Papillary Thyroid Cancer
- Trial name
- NCT00134043
- Testing
- vorinostat
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
This phase II trial studies the effect of selpercatinib given before surgery in treating patients with thyroid cancer whose tumors have RET alterations (changes in the genetic material [deoxyribonucleic acid (DNA)]).
- Conditions
- Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Thyroid Gland Anaplastic Carcinoma
- Trial name
- NCT04759911
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Selpercatinib
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma
Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
This phase II trial studies how well lenvatinib and pembrolizumab work in treating patients with anaplastic thyroid cancer that is stage IVB and has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed…
- Conditions
- Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8
- Trial name
- NCT04171622
- Testing
- Lenvatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
This phase II trial studies how well pembrolizumab and lenvatinib work in treating patients with differentiated thyroid cancer that has spread to other places in the body or has come back and cannot be removed by surgery.
- Conditions
- Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Metastatic Thyroid Gland Follicular Carcinoma, Metastatic Thyroid Gland Papillary Carcinoma
- Trial name
- NCT02973997
- Testing
- Laboratory Biomarker Analysis, Lenvatinib, Lenvatinib Mesylate
- Where
- 7 sites in United States
- Volunteers
- 57 people
- Sponsor
- Academic and Community Cancer Research United